0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comments and Opinions |

British Guidelines on the Use of Biological Therapies for Psoriasis: A Note of Clarification on the Role of Etanercept

Catherine H. Smith, MD, FRCP; Anthony D. Ormerod, FRCP
Arch Dermatol. 2007;143(12):1589-1603. doi:10.1001/archderm.143.12.1595-b.
Text Size: A A A
Published online

Extract

We are pleased that the British Association of Dermatologists guidelines on use of biological therapies in psoriasis1 have been highlighted and summarized so succinctly. We are also glad that the reviewing author, Dr Nijsten,2 found them to be “clear and informative” and that he recommends their use. However, we are concerned that his conclusion (as stated in the abstract and in the commentary) that “etanercept is the biological drug of choice in most eligible patients with stable disease with or without psoriatic arthritis” is a misrepresentation of what is stated in the guidelines. Indeed, we were very careful not to provide explicit guidance as to which of the agents covered (etanercept, infliximab, and efalizumab) should be the preferred choice given the lack of evidence available at the time.

Topics

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

46 Views
7 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();